Table 1.
Baseline characteristics of 13 non-comparative studies and patients
| Authors (year) [Ref] | Study Design | Region | Patients | CPS | BCLC | ECOG | Aetiology | Treatment | No. of TACE | Duration Time of sorafenib |
|---|---|---|---|---|---|---|---|---|---|---|
| Erhardt et al. (2014) [33] | Phase II | Germany | 38 | ≤8scores | NA | 0–2 | NA | Continuous sorafenib, interrupted only around TACE | 2.0(mean) | NA |
| Dufour et al. (2010) [34] | Phase I Open-label | Switzerland | 14 | A = 93% B = 7% | B = 64% C = 36% | 0 = 93% 1 = 7% | HCV = 29% | Sorafenib started 1 week prior to TACE without pause for TACE | 2.0(median) | NA |
| Cabrera et al. (2011) a [35] | Phase II Prospective | USA | 47 | A = 72% B = 28% | B = 81% C = 19% | 0 = 75% 1 = 25% | HCV = 60% | Continuous sorafenib started 2–4 weeks before DEB-TACE | 3.0(median) | NA |
| Lee et al. (2011) [36] | Phase II Prospective | South Korea | 59 | A = 93% B = 7% | B = 100% | NA | HBV = 88% | Sorafenib, TACE was performed at every 6–8 weeks | NA | NA |
| Pawlik et al. (2011) a [37] | Phase II Prospective | USA | 35 | A = 89% B = 11% | B = 34% C = 66% | 0 = 46% 1 = 54% | HCV = 37% | Continuous sorafenib started 1 week before DEB-TACE | 2.0(median) | NA |
| Park et al. (2012) [38] | Phase II Prospective | South Korea | 50 | A = 94% B = 6% | B = 82% C = 18% | 0 = 44% 1 = 56% | HBV = 68% HCV = 18% | Sorafenib started 3 days after TACE | 1.0(median) | 6 month |
| Sieghart et al. (2012) [39] | Phase I | Austria | 15 | A = 80% B = 20% | B = 70% C = 30% | 0 = 92% 1 = 8% | HBV = 4% HCV = 20% | Sorafenib started 2 weeks before the first TACE | 3.0(median) | 5.2 month (median) |
| Chung et al. (2013) [40] | Phase II Prospective | China and South Korea | 151 | A = 92% B = 8% | A = 16% B = 82% C = 1.9% | 0 = 82% 1 = 18% | NA | Sorafenib started 4–7 days after TACE | 2.1(mean) | NA |
| Zhao et al. (2013) [41] | Prospective | China | 222 | A = 86% B = 14% | B = 20% C = 80% | 0 = 44% 1 = 50% 2 = 6% | HBV = 80% HCV = 5% | Continuous sorafenib with no breaks before or after TACE | 2.0(median) | NA |
| Pan et al. (2014) [7] | Retrospective | China | 41 | A = 85.4% B = 14.6% | NA | 0 = 48.8% 1 = 51.2% | HBV = 97.6% HCV = 2.4% | Sorafenib was taken 3 days after the first TACE procedure | 2.0(median) | NA |
| Chao et al. (2014) [2] | Phase II Prospective | Taiwan | 192 | A = 91.8% B = 7.1% | A = 16.9% B = 81.5% C = 1.6% | 0 = 81.8% 1 = 17.7% 3 = 0.5% | NA | Sorafenib on day 4 (to day 7) after the first TACE (day 1) the interrupt on day 4 before the next TACE | 3.0(median) | NA |
| Yao et al. (2015) [32] | Retrospective | China | 50 | A = 88% B = 12% | B = 52% C = 48% | 0 = 46% 1 = 54% | HBV = 84% HCV = 4% | Sorafenib before and after 1 week of TACE | 3.0(median) | 1.4 month (median) |
| Cosgrove et al. (2015) a [42] | Phase II | USA | 50 | A = 92% B = 8% | A = 6% B = 32% C = 62% | 0 = 52% 1 = 48% | HBV = 8% HCV = 44% | Sorafenib was started 1 week before the first round of DEB-TACE | 2.0(median) | 1.5 month |
Abbreviations: BCLC The Barcelona Clinic Liver Cancer, CPS Child-Pugh classification, ECOG Eastern Cooperative Oncology Group, NO. number, NA not available, HBV hepatitis B virus, HCV hepatitis C virus
a TACE with drug-eluting beads (DEB) was performed in the studies. Patients in other studies treated with conventional TACE (c-TACE)